Titlebook: Macromolecular Anticancer Therapeutics; L. Harivardhan Reddy,Patrick Couvreur Book 2010 Springer-Verlag New York 2010 cancer.cancer therap

鍍金

kidney

袖章

Kenneth A. Foon,Michael Boyiadzis,Samuel A. Jacobsl cells in early development. Is their impact on life span related, at least partially, to their developmental functions or is it explained by other pleiotropic influences later in life? In this paper, we address this question based on the published data and our own findings.

Infusion

使隔離

HPMA-Anticancer Drug Conjugates Non-targeted and targeted polymer–drug derivatives based on HPMA have both cytostatic and immunostimulating activity. Their impressive anti-tumor effects most likely result from the combination of strong direct cytotoxicity and a systemic anticancer resistance regularly induced during the treatment

Nomogram

Poly-,-Glutamic Acid Anti-cancer Drug Conjugatesrge number of potential binding sites, high aqueous solubility, lack of immunogenicity, and its biodegradability. This chapter focuses on the developmental challenges associated with polymer therapeutics, using as an example, CT-2103, generically named paclitaxel poliglumex. Sections are devoted to

delta-waves

Polysaccharide-Based Anticancer Prodrugsrom poor physicochemical, biopharmaceutical, and therapeutic properties that limit their therapeutic performance and proper use in anticancer treatment. Polysaccharide-based anticancer prodrugs can be designed to endow derivatives with new bioresponse, targeting, or environmental triggering properti

Highbrow

即席

Lipid-Based Anticancer Prodrugstance is one of the most important clinical concerns. Thus, there is a real need to develop new chemical entities able to bypass the resistance factors, thus displaying an improved therapeutic response. In this context, lipid prodrugs of anticancer agents are important actors in overcoming the resis

污穢